Prestige Consumer Healthcare Inc. (PBH) Q3 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights mixed signals: strong e-commerce growth and product launches are positive, but inventory destocking and uncertain guidance create concerns. While management's optimism about Clear Eyes supply and stable margins is reassuring, the lack of specific guidance and volatility in retailer order patterns are drawbacks. Given the market cap, a neutral stock price movement is likely as positive and negative factors balance out.
Key Financial Performance
Sales $283 million, declined 2.4% year-over-year due to lower eye and ear care category sales, primarily from Clear Eyes supply constraints. However, growth in e-commerce and other channels offset some of the decline.
Gross Margin 55.5%, up 50 basis points year-over-year, driven by improved efficiencies and cost management.
Adjusted EPS $1.14, down from $1.22 year-over-year, reflecting lower sales, timing of advertising and marketing spend, and higher general and administrative costs.
Free Cash Flow $209 million year-to-date, up 13% year-over-year, attributed to strong cash generation and disciplined capital allocation.
Net Debt Approximately $1 billion, with a leverage ratio of 2.6x, reflecting strong financial positioning and debt reduction efforts.
Revenue (First 9 Months) Decreased 3.9% year-over-year organically, primarily due to Clear Eyes supply chain constraints and softness in analgesic and cough and cold categories.
International Segment Revenue Decreased 0.9% year-over-year, impacted by timing of distributor orders and limited eye care production.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Clear Eyes supply improvement: Sequential improvement in Clear Eyes supply for the second quarter in a row. Actions taken include bringing on 2 new third-party suppliers, acquiring Pillar5, and installing a new high-speed production line to support majority of eye care production internally.
E-commerce growth: Strong growth in e-commerce channels, offsetting negative trends in other channels.
Free cash flow: Generated $208.8 million in free cash flow year-to-date, up 12.9% versus the prior year. Full-year outlook is $245 million or more.
Capital allocation: Repurchased $46 million in stock during the quarter and acquired Pillar5 for $110 million. Year-to-date share repurchases total over $150 million, nearly 5% of shares outstanding.
Pillar5 acquisition: Acquired Pillar5 to take direct control over an important element of the supply chain, enabling higher production levels and improved supply chain efficiency.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Supply Chain Constraints: Challenges in maintaining consistent supply for the Clear Eyes brand due to prior supply chain issues. Efforts to address this include acquiring Pillar5 and adding new suppliers, but these transitions involve onetime investments and potential disruptions.
High Inflation: Persistent high inflation impacting consumer behavior and increasing operational costs, which could affect profitability and demand.
Geopolitical Events: Uncertainty from geopolitical events that could disrupt operations or supply chains.
Consumer Volatility: Changing consumer shopping habits and softness in certain categories like analgesics and cough and cold, leading to unpredictable demand patterns.
Supplier Loan Write-Off: A $10 million write-off of a supplier loan due to the supplier's business closure, highlighting risks in supplier financial stability.
Category Softness: Declines in sales for certain categories, including analgesics and cough and cold, which could impact overall revenue.
Regulatory and Tariff Costs: Ongoing tariff costs of approximately $5 million for fiscal year 2026, adding to operational expenses.
Bad Debt Allowance: Increased bad debt allowance for a specific customer, indicating potential credit risks.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Outlook: The company has narrowed its fiscal 2026 sales outlook to approximately $1.1 billion, reflecting growth in channels like mass and e-commerce, offset by slower order patterns in other channels.
Clear Eyes Supply Improvement: Sequential improvement in Clear Eyes supply is expected in Q4, marking three consecutive quarters of improvement. The company anticipates further production increases throughout calendar 2026.
Adjusted EPS: The adjusted diluted EPS for fiscal 2026 is anticipated to be approximately $4.54, following the narrowed sales outlook.
Free Cash Flow: The company continues to anticipate free cash flow of $245 million or more for fiscal 2026, with lower Q4 free cash flow expected due to timing and investments in working capital.
Gross Margin: A 57% adjusted gross margin is anticipated for Q4 fiscal 2026.
Capital Deployment: The company plans to continue disciplined cash deployment, including investments in brands, M&A opportunities, share repurchases, and deleveraging. Over $150 million in shares have been repurchased year-to-date, representing nearly 5% of shares outstanding.
Eye Care Category Growth: Long-term growth opportunities in the eye care category are anticipated, driven by an aging population and other factors. The company expects to diversify production into an expanded assortment of SKUs as production levels increase.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: The company repurchased approximately $46 million in stock during the third quarter of fiscal 2026. Year-to-date, the company has repurchased over $150 million in shares, representing nearly 5% of shares outstanding. The majority of these repurchases occurred in Q2 and Q3, executed opportunistically at attractive return levels. This is part of a multiyear share repurchase authorization.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are you seeing consumption shift to other retailers, or is it more about inventory stocking in weaker parts of your distribution?
A:Ron Lombardi explained that the environment is volatile, with a continuation of a channel shift. They are picking up consumption based on where customers purchase products, reflecting trends discussed earlier in the year.
Q:Do you feel good about the overall consumption trends within the business, and is the inventory destocking impacting the guidance?
A:Ron Lombardi confirmed that they feel good about overall consumption trends. The inventory destocking is impacting the guidance, but the diverse portfolio and broad distribution help mitigate the impact.
Q:When do you expect the inventory headwind to go away? Is it specific to Q4 or will it extend into the next fiscal year?
A:Ron Lombardi stated that they are looking at it quarter-by-quarter and it is hard to predict. The volatility seen in the past makes it challenging to forecast, but the company is well-positioned to manage through it.
Q:Are there any initial factors to consider for the next fiscal year, particularly regarding Clear Eyes or other areas?
A:Ron Lombardi mentioned they feel good about the organic performance of the business and expect continued increases in the Clear Eyes supply chain. More details will be provided in the May call.
Q:What is the status of restocking in the eye care business, and is there an impact on margins during the disruption?
A:Christine Sacco stated that restocking will take time and is expected to continue through fiscal '27. Margins are relatively stable, with no meaningful change expected as the business normalizes.
Q:Can you provide an update on e-commerce penetration and areas of faster growth online?
A:Ron Lombardi reported over 10% consumption growth in the third quarter. E-commerce growth is driven by broad product offerings, pricing transparency, and service. The company works with retail partners to meet shopper objectives.
Q:What is the update on the women's health business, particularly Monistat and Summer's Eve?
A:Ron Lombardi noted that Monistat is performing well with historic peak levels of share, while Summer's Eve is positioned for long-term growth despite year-to-year volatility. The overall women's health franchise is doing well.
Q:Why has there been an increase in stock buybacks, and is this a trend to expect going forward?
A:Christine Sacco explained that investing in brands is the priority, but stock buybacks are evaluated based on market conditions and returns for shareholders. This is secondary to M&A and does not impact brand investments.
Q:Why does the guidance for the fourth quarter imply slower growth despite third-quarter sales being slightly ahead of expectations?
A:Ron Lombardi clarified that the guidance reflects volatility in retailer order patterns, not a consumption issue. Retailers with headwinds are adjusting their orders, which impacts the outlook.
Q:What was the consumption trend in the third quarter, and what is expected for the fourth quarter?
A:Ron Lombardi highlighted strong performance in GI and skin categories, while lice and analgesics faced challenges. Fourth-quarter consumption is expected to align with targets, excluding specific outliers like lice and cough/cold.
Q:Does the improving supply in the eye and ear care segment suggest an above-algorithm year for fiscal '27?
A:Ron Lombardi stated that they feel good about the broad portfolio and Clear Eyes supply improvements. More details will be provided in the May call.
Q:Will e-commerce growth lead to changes in advertising and marketing strategies?
A:Ron Lombardi mentioned that marketing evolves to connect with shoppers as they shop differently. The focus is on long-term brand building rather than cost savings.
Q:Is private label gaining share in the current environment?
A:Ron Lombardi stated that private label share remains stable, as consumers prefer trusted brands for infrequent purchases.
Q:Will the recovery of the eye care business require additional marketing focus?
A:Ron Lombardi confirmed that marketing spending for Clear Eyes will increase as more products become available, but funds will be shifted from other areas without impacting the P&L profile.
Q:Are there any new product launches or line extensions planned for 2027?
A:Ron Lombardi highlighted the launch of Compound W's skin tag product, which has become the #1 product in its category at mass retailers and online.
Q:What was the nature of the financial assistance provided to a supplier, and what was the outcome?
A:Christine Sacco explained that $8 million was extended to a supplier facing financial difficulties to ensure continuity of supply. The products were successfully transferred to other facilities before the supplier shut down.
Q:Is future M&A focused on brands or facilities?
A:Ron Lombardi stated that future M&A will focus on brands and long-term brand-building value.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the question about when the inventory headwind may go away, citing unpredictability and volatility. Additionally, they deferred providing specific details about fiscal '27 performance and product launches until the May call.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Clear Eyes
Eyes supply
GA
Pillar share
Slide date
action
analgesic cough
brand
capital deployment
care production
chain
closure Pillar
constraint
consumer backdrop
date share
debt
effort
eye care
factor
focus
loan
month
outlook
presentation today
production level
production term
result
revenue
risk
share repurchase
side page
slide presentation
supplier
value priority
PBH Transcript
Prestige Consumer Healthcare Inc. (PBH) Q3 2026 Earnings Call Transcript
Unknown2-5
The earnings call highlights mixed signals: strong e-commerce growth and product launches are positive, but inventory destocking and uncertain guidance create concerns. While management's optimism about Clear Eyes supply and stable margins is reassuring, the lack of specific guidance and volatility in retailer order patterns are drawbacks. Given the market cap, a neutral stock price movement is likely as positive and negative factors balance out.
Prestige Consumer Healthcare Inc. (PBH) Q2 2026 Earnings Call Transcript
Unknown11-6
The earnings call summary reflects a mix of positive and negative elements. Basic financial performance is challenged by supply chain issues and declining revenue guidance, while product development and market strategy show potential for recovery and growth. Expenses are manageable with expected cash flow, but the lack of clear guidance and uncertainties in specific areas like Clear Eyes recovery and e-commerce order patterns contribute to a neutral sentiment. Given the market cap, the stock is likely to experience minor fluctuations, resulting in a neutral prediction for the next two weeks.
Prestige Consumer Healthcare Inc. (PBH) Presents at Barclays 18th Annual Global Consumer Staples Conference 2025 Transcript
Neutral9-5
Prestige Consumer Healthcare Inc. (PBH) Q1 2026 Earnings Call Transcript
Unknown8-8
The earnings call revealed mixed signals. Strong revenue growth and capacity expansion plans are positive, but ongoing margin pressures and supply chain issues in eye care are concerning. The Q&A session highlighted confidence in supply normalization and strategic M&A, yet lacked clarity on certain impacts and specific metrics. Considering the market cap, these factors suggest a neutral stock price movement.
PBH Slides
PBH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
